Market research
TRIL Trillium Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 23.41
- Dividend yield
- 0.0%
- Beta
- 0.0
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA89620X5064
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 23.41
- Dividend yield
- 0.0%
- Beta
- 0.0
About
About Trillium Therapeutics Inc
Under normal circumstances, the fund will invest at least 80% of its net assets, plus borrowings for investment purposes, in equity securities of Trillion Companies and/or financial instruments (such as swaps) that provide indirect exposure to Trillion Companies. The index tracks the performance of U.S. exchange-listed companies with market capitalizations of $1 trillion or greater ("Trillion Companies"). The fund is non-diversified.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TRIL discussion.
5 years, 4 months ago
Trillium Therapeutics Inc is currently in a long term downtrend where the price is trading 25.7% below its 200 day moving average.
From a valuation standpoint, the stock is 363.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6202.2.
Trillium Therapeutics Inc's total revenue sank by 73.4% to $33K since the same quarter in the previous year.
Its net income has increased by 373.1% to $114M since the same quarter in the previous year.
Finally, its free cash flow fell by 9.1% to $-5M since the same quarter in the previous year.
Based on the above factors, Trillium Therapeutics Inc gets an overall score of 1/5.